✦ LIBER ✦

Non-small cell lung carcinoma of the superior sulcus: The evolution of treatment outcomes with multimodality treatment at a single institution

✍ Scribed by Tetsuzo Tagawa; Atsushi Osoegawa; Koji Yamazaki; Tatsuro Okamoto; Takuro Kometani; Hiroshi Wataya; Takashi Seto; Seiichi Fukuyama; Fumihiko Hirai; Kenji Sugio; Yukito Ichinose

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 76 KB
Volume: 101
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.21507

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment outcomes of small cell carcino

Treatment outcomes of small cell carcinoma of the prostate : A single-center study

✍ Philippe E. Spiess; Curtis A. Pettaway; Funda Vakar-Lopez; Wassim Kassouf; Xueme 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

## Abstract ## BACKGROUND. The current study was conducted to determine the clinical characteristics and prognostic features associated with prostatic small cell carcinoma (SCC). ## METHODS. Between January 1985 and May 2005, 83 patients with SCC of the prostate were identified. Univariate and m

Clustered incidence of acute promyelocyt

Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: Experience at a single institution

✍ Keitaro Matsuo; Katsuyuki Kiura; Masahiro Tabata; Akiko Uchida; Katsuyuki Hotta; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 1 views

Cisplatin, etoposide, and mitomycin in t

Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study

✍ Stephen Davis; Maurizio Tomato; Lucio Crino; Mari Antonetta Colozza; Kenneth Lub 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 2 views

A total of 39 patients with non-small cell carcinoma of the lung (NSCL) were treated with cisplatin, etoposide, and mitomycin. A major response rate (complete response + partial response) was seen in 15 patients (39%). Median survival for all patients was 340 days; median survival of the responding

Cisplatin, continuous-infusion 5-fluorou

Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small cell carcinoma of the lung

✍ Catherine A. Wheeler; Lawrence N. Shulman; Steven E. Come; Lowell E. Schnipper; 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 377 KB 👁 2 views

Forty-one patients with unresectable non-small cell carcinoma of the lung (NSCCL) were treated with cisplatin 20 mg/m2/d for 5 days as a daily bolus injection, 5-fluorouracil 800 mg/m2/d by continuous infusion for 5 days, and intermediate-dose methotrexate 200 mg/m2 on days 15 and 22 of a 28-day cyc

Teniposide (VM-26) as a single drug trea

Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma : A Phase II study of the Southwest Oncology Group

✍ Petre N. Grozea; John J. Crowley; Vikki A. Canfield; Laura Kingsbury; S. William 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 3 views

## Background: Teniposide (vm-26) was reported to have activity in small cell lung carcinoma (sclc). the authors performed a phase ii study of teniposide as a treatment for patients with previously untreated extensive sclc. ## Methods: The study was open to patients with a histologic or cytologic

Teniposide (VM-26) as a single drug trea

Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: A phase II study of the southwest oncology group

✍ Jacob J. Lokich 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 3 views